×

Biotech and Pharmaceuticals Life Sciences

  • NEW HAVEN, Conn. _ Achillion Pharmaceuticals Inc. on Thursday reported a fourth-quarter loss of $4.4 million, after reporting a profit in the same period a year earlier. The New Haven, Connecticut- based company said it had a loss of 3 cents per share. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.

  • BOULDER, Colo. _ Clovis Oncology Inc. on Wednesday reported a loss of $70.7 million in its fourth quarter. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.65 per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • Feb 21- Drugmaker Bristol-Myers Squibb Co said on Tuesday it appointed three directors to its board in an agreement with JANA Partners LLC, an activist investor holding less than 1 percent of the company's stock. The stock fell 1.8 percent to $53.59 on Tuesday. New York- based JANA owned 3.9 million shares of Bristol-Myers as of Dec. 31, a $226 million stake well...

  • SOUTH SAN FRANCISCO, Calif. _ Cytokinetics Inc. on Thursday reported fourth-quarter net income of $7.2 million, after reporting a loss in the same period a year earlier. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share. Cytokinetics shares have fallen 7 percent since the beginning of the year.

  • CAMBRIDGE, Mass. _ Agios Pharmaceuticals Inc. on Thursday reported a loss of $56.5 million in its fourth quarter. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.55 per share. Agios Pharmaceuticals shares have risen 11 percent since the beginning of the year.

  • WASHINGTON _ Vanda Pharmaceuticals Inc. on Wednesday reported a loss of $604,000 in its fourth quarter. The Washington- based company said it had a loss of 1 cent per share. For the year, the company reported that its loss narrowed to $18 million, or 41 cents per share.

  • MENLO PARK, Calif. _ Corium International Inc. on Monday reported a loss of $10.4 million in its fiscal first quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. Three analysts surveyed by Zacks expected $8.2 million.

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drug makers, according to people familiar with the matter. Tesaro is not actively exploring a sale, the people said this week, noting that there is a significant gap over the company's valuation between Tesaro and...

  • Songjiang Wang, who Cambridge, Massachusetts- based Merrimack has employed as director of statistical programming since 2011, was charged with conspiring to commit securities fraud in a criminal complaint filed in federal court in Boston. He was arrested after prosecutors brought related charges in June against Schultz Chan, who had been the director of...

  • Feb 2- The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer. Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy,...

  • *Q4 core EPS $1.21 vs consensus forecast $1.13. LONDON, Feb 2- AstraZeneca warned on Thursday that profit and revenue would both fall this year as cheap generic versions of its cholesterol drug Crestor continue to hit sales. Chief Executive Pascal Soriot reaffirmed his confidence in the trial, despite recent mixed developments in the hotly contested cancer...

  • *Qtrly Prevnar sales fall 23 pct to $1.42 bln. Jan 31- Pfizer Inc, which closed its $14 billion acquisition of Medivation Inc in September, reported a lower-than-expected profit, hit by lower demand for its flagship vaccine Prevnar and higher expenses. Pfizer earned an adjusted profit of 47 cents per share, missing the average analysts' estimate of 50 cents,...

  • Biotech is a critical business

    Joel Marcus, Alexandria Real Estate equities, talks about the immigration ban, and the benefits of tax repatriation from the biotech industry.

  • Jan 26- Bristol-Myers Squibb Co on Thursday posted a fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker cut its adjusted earnings per share outlook by 15 cents to between $2.70 and $2.90.

  • Jan 26- Bristol-Myers Squibb Co on Thursday posted fourth-quarter profits that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker said it now expects adjusted earnings of $2.70 to $2.90 per share, down from its previous range of...

  • Jan 26- Bristol-Myers Squibb Co on Thursday reported fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker said it now expects adjusted earnings of $2.70 to $2.90 per share, down from its previous range...

  • Jan 25- Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionising cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for "a leadership position in oncology" by...

  • Jan 25- Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionising cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for "a leadership position in oncology" by...

  • Jan 25- Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for "a leadership position in oncology" by...